Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YSSTK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
muFR1-13-PEG4-Mal-DM4
|
|||||
| Synonyms |
muFR1 13 PEG4 Mal DM4
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
mu-FR1-13
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PEG4-Mal
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 18.22
|
%
|
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.15
|
nM
|
SK-OV-3 cells
|
Ovarian serous cystadenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 18.22% (Day 22) | Positive FOLR1 expression (FOLR1 +++/++) | ||
| Method Description |
PEG4Mal-DM4 conjugates of the exemplary anti-FOLR1 antibodies were tested using an established xenograft model of KB cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once on day 3 post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | KB CDX model | ||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.15 nM | Positive FOLR1 expression (FOLR1 +++/++) | ||
| Method Description |
FOLR1-expressing SKOV3 cells were incubated with varying concentrations of anti FOLR1 antibodies or their conjugates and processed.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.